Search
- Aug 2, 2023
How a new CEO has been trying to position Editas to execute on the promise of CRISPR
Gilmore O’Neill is working to inject stability and focus at Editas as it aims to execute on both ex-vivo and in-vivo crispr gene therapies.
Also look for unique social pages for BiotechTV U.
#1. Ultragenyx's Emil Kakkis on Angelman syndrome data, rare disease treatment modalities, and more
#2. The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease
#3. Sutro Biopharma's CEO on ADCs, non-cell protein synthesis, and more
#4. Verve Therapeutics' CEO on today's gene editing clinical trial pause
#5. Daphne Zohar on becoming the CEO of Seaport Therapeutics and a $100M series A